Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Carboplatin
Related studies linked through entity extraction aliases.
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
- Status
- COMPLETED
- Phase
- PHASE2
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
- Status
- TERMINATED
- Phase
- PHASE2
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
- Status
- COMPLETED
- Phase
- PHASE3
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
- Status
- WITHDRAWN
- Phase
- PHASE2
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2